(Total Views: 622)
Posted On: 03/05/2021 8:36:22 PM
Post# of 151807
Primary End-Point! "Survival benefit: There was a 24% reduction in all-cause mortality (primary endpoint of the study) in the leronlimab versus placebo." -CytoDyn PR 3/5/21
Boom.
https://tylerpaper.com/ap/business/cytodyn-s-...f58a8.html
Boom.
https://tylerpaper.com/ap/business/cytodyn-s-...f58a8.html
(3)
(0)Scroll down for more posts ▼
